Global Cancer Treatment Forecast to 2012

Global Cancer Treatment Forecast to 2012

High number of unmet needs and an ever-increasing prevalence of cancer has created a gold rush among drug companies to enter the cancer market. Here, launching a drug successfully is risky, however, if launched, commercial gains completely surpass the expenditures incurred, says ````Global Cancer Treatment Forecast to 2012”, the new research report from RNCOS.

Cancer represents the fastest growing therapy segment in the pharmaceutical market. This segment has become the centre of focus for drug firms and investors, and has garnered more attention than any other therapy segment; nearly every mid-size and large pharmaceutical/biotech company today is linked to a cancer pipeline.

Drugs available in the market today do give some respite to patients but fail to address a number of complications. So manufacturers are working to solve the problem and in future, we may see a number of drug launches which will significantly reduce the complications and increase life expectancy significantly.

This report is a comprehensive study on the global cancer market and gives statistics and analysis on cancer prevalence, market size, market structure, key drug segments, market share of key players and drugs, major opportunity areas and trends in technology development. Both the past and current market trends have been covered in the report along the factors that are expected to impact the market in future. This report provides answers to a number of questions vital for firms looking for making an investment into the sector.

Key Findings

• From more than 12 Million newly diagnosed cancer cases in 2007, the number of newly diagnosed global cancer cases is expected to reach over 17 Million by 2020.
  
  
• Growing at a CAGR of 12.3% between 2007 and 2012, the global market for cancer drugs is expected to cross US$ 78 Billion by 2012.
  
  
• Cancer vaccines and antiangiogenics will record the fastest growth rate between 2007 and 2012.
  
  
• Drug manufactures are now focused on developing target therapies. These drugs attack target cells and thus limit the severity of side effects.
  
  
• The US is the largest market for cancer drugs, followed by Europe and Japan.
  
  
• Drugs for cancer represent the largest therapy area under clinical development; however, when it comes to approval rates, drugs for cancer have the worst approval rates.

Key Issues Analyzed

• Evaluation of past, current and future market trends.
  
  
• Discussion on major cancer drugs and their markets.
  
  
• Future forecast of the cancer market.
  
  
• Analysis of various challenges and opportunities for the industry.
  
  
• Categories of players operating in the market and their present and future revenue forecast.
  
  
• Analysis of key Geographical markets

Research Methodology Used

Information Sources
The information given in the report has been sourced from various credible sources like books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to over 3000 paid databases.

Analysis Methods
The analysis methods used in the report include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting, and cause and effect analysis. 
 

1. Analyst View

2. The Global Burden of Cancer

2.1 Cancer - A Leading Cause of Death

2.2 Prevalence

2.3 Factors Inducing Cancer

3. Global Cancer Market

3.1 Market Size

3.2 Market Segmentation

3.3 Drug Pipelines

3.4 Key Players

3.5 Key Drugs

4. Current & Future Treatments

4.1 Chemotherapy

4.1.1 Introduction

4.1.2 Market Analysis

4.1.2.1 Plant Alkaloids

4.1.2.2 Alkylation Agents

4.1.2.3 Anti-metabolites

4.1.2.4 Platinum Compounds

4.1.2.5 Cytotoxic Antibiotics

4.1.2.6 Other Cytostatics

4.2 Antiangiogenics

4.2.1 Introduction

4.2.2 Market Analysis

4.3 Hormone Therapy

4.3.1 Introduction

4.3.2 Market Analysis

4.4 Monoclonal Antibodies

4.4.1 Introduction

4.4.2 Market Analysis

4.5 Vaccines

4.5.1 Introduction

4.5.2 Market Analysis

5. Key Markets

5.1 US

5.1.1 Prevalence

5.1.2 Market Analysis

5.2 Europe

5.2.1 Prevalence

5.2.2 Market Analysis

5.3 Japan

5.3.1 Prevalence

5.3.2 Market Analysis

5.4 India & China

5.4.1 Prevalence

5.4.2 Market Analysis

6. Opportunities

6.1 Drug Delivery & Packaging Market

6.2 Diagnostic Devices

6.3 Cancer Generics

6.4 Contract Research & Manufacturing

7. Roadblocks

7.1 High Clinical Failure Rates

7.2 Reimbursements

7.3 Affordability

7.4 Side Effects

List of Figures:

Figure 2-1: Global - Leading Causes of Death (%), 2005E

Figure 2-2: Global - New Cancer Cases* (in Million), 2002, 2007, 2012F & 2020F

Figure 2-3: Global - New Cancer Cases* in Males by Type (%), 2007E

Figure 2-4: Global - New Cancer Cases* in Females by Type (%), 2007E

Figure 2-5: Global - New Cancer Cases by Region (in Number), 2007E

Figure 2-6: Global - Leading Causes of Cancer (%)

Figure 3-1: Global - Cancer Market (in Billion US$), 2007-2012F

Figure 3-2: Global - Cancer Market by Drug Type (%), 2007

Figure 3-3: Global - Forecast for Cancer Market by Drug Type (%), 2012

Figure 3-4: Global - Drugs under Clinical Development by Therapy Area (%), 2007

Figure 3-5: Global - Cancer Drugs by Type in Phase-II Clinical Development Process (%), 2006

Figure 3-6: Global - Cancer Drugs by Type in Phase-III Clinical Development Process (%), 2006

Figure 3-7: Global - In-licensing Deals by Therapy Area (%), 2006

Figure 4-1: Global - Chemotherapy Market (in Million US$), 2007-2012F

Figure 4-2: Global - Plant Alkaloids Market (in Million US$), 2007-2012F

Figure 4-3: Global - Alkylation Agents Market (in Million US$), 2007-2012F

Figure 4-4: Global - Anti-metabolites Market (in Million US$), 2007-2012F

Figure 4-5: Global - Platinum Compounds Market (in Million US$), 2007-2012F

Figure 4-6: Global - Cytotoxic Antibiotics Market (in Million US$), 2007-2012F

Figure 4-7: Global - Other Cytostatics Market (in Million US$), 2007-2012F

Figure 4-8: Global - Antiangiogenics Market (in Million US$), 2007-2012F

Figure 4-9: Global - Hormone Therapy Market for Cancer Treatment (in Million US$) 2007-2012F

Figure 4-10: Global - Hormone Therapy Market Segmentation for Cancer Treatment (%), 2004 & 2014F

Figure 4-11: Global - Monoclonal Antibodies Market (in Million US$), 2007-2012F

Figure 4-12: Global - Cancer Vaccine Market (in Million US$), 2006, 2007E & 2012F

Figure 4-13: Global - Cancer Vaccine by Type in various Phases of Clinical Development (in Number), Aug 2005

Figure 5-1: US - New Cancer Cases* (in Number), 2005, 2008F & 2012F

Figure 5-2: US - Cancer Market (in Million US$) 1999, 2004, 2007E & 2012F

Figure 5-3: US - Cancer Market by Therapy Area (%) 1999, 2004, 2007E & 2012F

Figure 5-4: Europe - New Cancer Cases* (in Number), 2004, 2006 & 2012F

Figure 5-5: Europe - Cancer Market (in Billion US$), 2004, 2007E & 2012F

Figure 5-6: Japan - Cancer Market (in Billion US$), 2005, 2007E & 2012F

Figure 5-7: India - New & Total Number of Cancer Patients (in Million)

Figure 5-8: China - New & Total Number of Cancer Patients (in Million)

Figure 5-9: India - Cancer Market (in Million US$), 2007 & 2012F

Figure 6-1: Global - Cancer Drug Delivery Market (in Billion US$), 2005E, 2010F & 2015F

Figure 6-2: Global - Cancer Diagnostics Market (in Billion US$), 2002, 2007E & 2012F

Figure 6-3: Global* - Cancer Drugs going Off-patent (in Billion US$), 2008-2014

Figure 6-4: Global* - Cancer Generic Market (in Billion US$), 2004, 2005, 2007E & 2014F

Figure 6-5: Global* - Cancer Generic Market by Country (%), 2005

Figure 7-1: Success Rates of Drugs by Therapy Area from First in Man to Registration (%)

List of Tables:

Table 2-1: Global - New Cancer Cases* in Males by Type (in Number), 2007E

Table 2-2: Global - New Cancer Cases* in Females by Type (in Number), 2007E

Table 3-1: Global - Revenues from Major Therapy Areas (in Million US$), 2007 & 2012F

Table 3-2: Global - Growth of various Cancer Drugs (%), 2007-2012

Table 3-3: Global - Sales of Top Companies in Cancer Market* (in Million US$), 2007

Table 3-4: Global - Forecast for Sales of Top Companies in Cancer Market* (in Million US$), 2012

Table 3-5: Global - Sales* of Top Cancer Drugs (in Billion US$), 2002

Table 3-6: Global - Sales* of Top Cancer Drugs (in Billion US$), 2006

Table 3-7: Global - Forecast for Sales* of Top Cancer Drugs (in Billion US$), 2012

Table 5-1: US - New Cancer Cases* for Selected Cancer Sites (in Number), 2008F

Table 5-2: US - Key Players in the Cancer Market by Rank (2000 & 2005)

Table 5-3: Europe - New Cancer Cases in Top 5 Countries (in ‘000), 2006

Table 5-4: Japan - Leading Sites of Cancer Incidences in Males & Females (%), 2001

Table 6-1: Global - Cancer Diagnostics Market by Type of Test (in Million US$), 2002-2006E